Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B013 + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Shanghai Cross-linked Pharmaceutical Research and Development
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
B013 + nab-paclitaxel is a combination therapy under investigation for the treatment of locally advanced or metastatic triple negative breast cancer (TNBC). Nab-paclitaxel, also known as Abraxane, is a nanoparticle albumin-bound formulation of the chemotherapy drug paclitaxel. It works by inhibiting cell division through stabilization of microtubules, thereby blocking cancer cell proliferation. The mechanism and modality of B013 are not specified in available sources; however, it is being studied in combination with nab-paclitaxel in Phase II/III clinical trials for TNBC[3][1][2]. Nab-paclitaxel is approved for use in metastatic breast cancer, non-small cell lung cancer (NSCLC), and pancreatic adenocarcinoma[2][4][7]. The developer or manufacturer information for B013 specifically is not available.
- Other names
- paclitaxel protein-boundalbumin-bound paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on B013 + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B013 + nab-paclitaxel.